SCHEMBL6310501

SCHEMBL6310501

CCC(Cc1c(C)c(C#N)c2nc3ccccn3c2c1Cl)OC(C)=O

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.36
HSD17B10 Q99714 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ALDH1A1 P00352 6/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MAPK1 P28482 3/20 0.34
SMN1; SMN2 Q16637 5/20 0.34
RAB9A P51151 5/20 0.34
GAA P10253 4/20 0.34
POLB P06746 1/20 0.33
KMT2A Q03164 4/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
NPC1 O15118 2/20 0.32
MAPT P10636 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6311689 0.81 ALDH1A1 (0.40) KDM4EHSD17B10NPSR1ALDH1A1RXFP1
SCHEMBL6318124 0.81 ALDH1A1 (0.43) KDM4EHSD17B10NPSR1ALDH1A1RXFP1
SCHEMBL6310328 0.80 NPSR1 (0.44) KDM4EHSD17B10NPSR1ALDH1A1RXFP1
SCHEMBL6312086 0.78 MAPT (0.47) KDM4EHSD17B10NPSR1ALDH1A1SMN1; SMN2
SCHEMBL6311562 0.76 HPGD (0.43) KDM4EHSD17B10NPSR1ALDH1A1SMN1; SMN2
SCHEMBL6310742 0.76 HPGD (0.43) KDM4EHSD17B10NPSR1ALDH1A1SMN1; SMN2
SCHEMBL6311004 0.76 ENPP2 (0.43) KDM4EHSD17B10NPSR1ALDH1A1MAPK1
SCHEMBL6311104 0.76 ENPP2 (0.41) KDM4ENPSR1ALDH1A1RXFP1MAPK1
SCHEMBL6312786 0.75 KDM4E (0.44) KDM4EHSD17B10NPSR1ALDH1A1RXFP1
SCHEMBL6317979 0.73 ADORA3 (0.43) KDM4ENPSR1ALDH1A1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-05-26 US disclosed
EP-1479681-A1 IMIDAZO(1,2-a)PYRIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative MANBA, MAN2B1, ERG28 KDM4E 3360/4885HSD17B10 4223/4885NPSR1 1531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.